What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Buy
56
PRTC Quote, Financials, Valuation and Earnings
Last price:
$16.85
Seasonality move
:
4.13%
Day range:
$16.91 - $16.91
52-week range:
$13.30 - $23.35
Dividend yield:
0%
P/E ratio:
9.57x
P/S ratio:
66.19x
P/B ratio:
1.02x
Volume:
481
Avg. volume:
3.9K
1-year change:
-19.17%
Market cap:
$408.1M
Revenue:
$4.8M
EPS (TTM):
$1.65
Analysts' Opinion
-
Consensus RatingPureTech Health Plc has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $46.00, PureTech Health Plc has an estimated upside of 172.03% from its current price of $16.91.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $46.00 representing 100% downside risk from its current price of $16.91.
Fair Value
-
According to the consensus of 1 analyst, PureTech Health Plc has 172.03% upside to fair value with a price target of $46.00 per share.
PRTC vs. S&P 500
-
Over the past 5 trading days, PureTech Health Plc has underperformed the S&P 500 by -5.73% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
PureTech Health Plc does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PureTech Health Plc has grown year-over-year revenues for 0 quarters straight. In the most recent quarter PureTech Health Plc reported revenues of --.
Earnings Growth
-
PureTech Health Plc has grown year-over-year earnings for 0 quarters straight. In the most recent quarter PureTech Health Plc reported earnings per share of --.
Enterprise value:
52.3M
EV / Invested capital:
--
Price / LTM sales:
66.19x
EV / EBIT:
1.55x
EV / Revenue:
-26.28x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.40x
Gross Profit (TTM):
$2.9M
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-15 | 2024-12-15 | 2024-12-15 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $451.1M | $381.8M | $360.1M | $508.8M | -- | |
| Total Assets | $896.9M | $823.2M | $693.6M | $580M | -- | |
| Current Liabilities | $213.9M | $150.3M | $49.3M | $138.3M | -- | |
| Total Liabilities | $335.5M | $247.1M | $184.7M | $273.7M | -- | |
| Total Equity | $561.4M | $576M | $508.9M | $306.2M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-15 | 2024-12-15 | 2024-12-15 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
PRTC
Sector
Market Cap
$408.1M
$29M
Price % of 52-Week High
72.42%
52.89%
Dividend Yield
0%
0%
Shareholder Yield
0.65%
-1.4%
1-Year Price Total Return
-19.17%
-19%
Beta (5-Year)
1.127
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$16.99
200-day SMA
Sell
Level
$17.55
Bollinger Bands (100)
Sell
Level
16.23 - 18.49
Chaikin Money Flow
Sell
Level
-393.5K
20-day SMA
Buy
Level
$16.48
Relative Strength Index (RSI14)
Buy
Level
51.20
ADX Line
Buy
Level
9.72
Williams %R
Neutral
Level
-50
50-day SMA
Sell
Level
$17.19
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
160K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7084)
Sell
CA Score
(Annual)
Level (-0.5937)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-3.2193)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, PRTC has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PRTC average analyst price target in the past 3 months is $46.00.
-
Where Will PureTech Health Plc Stock Be In 1 Year?
According to analysts, the consensus estimate is that PureTech Health Plc share price will rise to $46.00 per share over the next 12 months.
-
What Do Analysts Say About PureTech Health Plc?
Analysts are divided on their view about PureTech Health Plc share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PureTech Health Plc is a Sell and believe this share price will drop from its current level to $46.00.
-
What Is PureTech Health Plc's Price Target?
The price target for PureTech Health Plc over the next 1-year time period is forecast to be $46.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PRTC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PureTech Health Plc is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of PRTC?
You can purchase shares of PureTech Health Plc via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PureTech Health Plc shares.
-
What Is The PureTech Health Plc Share Price Today?
PureTech Health Plc was last trading at $16.85 per share. This represents the most recent stock quote for PureTech Health Plc. Yesterday, PureTech Health Plc closed at $16.91 per share.
-
How To Buy PureTech Health Plc Stock Online?
In order to purchase PureTech Health Plc stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PRTC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PRTC
Sector
P/E ratio
9.57x
24.19x
PEG ratio
--
-0.01x
P/B ratio
1.02x
1.84x
Price / LTM sales
66.19x
1.61x
Growth Metrics
PRTC
Sector
Revenue growth
--
4.6%
Earnings growth
--
10.88%
Revenue (5-year growth)
-13.21%
6.5%
Earnings forecast
--
-$0.20
Profitability
PRTC
Sector
Profitability FY 2024
$1.3M
$3.5M
Return on invested capital
--
-31.66%
Return on assets
--
-27.84%
Return on equity
--
-37.15%
Earnings Date
Last Earnings Date
Aug
28
Next Earnings Date
Apr
30
Estimated Next Earnings Date
Nov
27
Balance Sheet
PRTC
Sector
Total cash
$502.1M
$26.8M
Short term investments
$86.7M
$26M
Total assets
$602.6M
$79.7M
Long term debt
--
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 8.31% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.3% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 4.4% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
